"My work centers on identifying and characterizing novel kinase inhibitors of disease-associated mutant kinases and understanding the downstream signaling of kinases commonly activated in human cancers. My future career goals are to learn more about kinase-regulated processes and to develop novel therapeutics against kinase-driven diseases."
Nurses from a range of departments at Fox Chase Cancer Center recently came together to put on a taco night for guests staying at the nearby AstraZeneca Hope Lodge of the American Cancer Society. Hope Lodge offers lodging at no cost for out-of-area cancer patients being treated in the Philadelphia area.
This month, we are highlighting a Phase 2 Clinical Trial for patients diagnosed with muscle invasive bladder cancer that will be led by Daniel M. Geynisman, MD, a medical oncologist at Fox Chase who specializes in genitourinary cancers.
Fox Chase Cancer Center researchers have identified a way forward for personalized cancer treatments for a wide range of cancers. Their findings can provide new insight into the mechanisms of a small molecule and investigational new drug for cancer called ONC201. The drug not only stimulates a powerful anticancer protein called TRAIL, but also the death receptor for TRAIL (also known as DR5) on tumor cells. This allows TRAIL to specifically kill tumor cells.